Hamide Kart KÖSEOĞLU, Tolga Enver YÜCETÜRK, Nilüfer BAYRAKTAR, Müge Aydın TUFAN, Murat GENCER, Ahmet Eftal YÜCEL

Anti-CCP Antibodies in Behcet's Disease with or without articular Involvement

Amaç: Eklem tutulumu Behçet hastalığının (BH) önemli bir bileşenidir ve bazen ayırıcı tanıyı zor hale getiren tek başlangıç bulgusu olabilir. Siklik sitrüline peptid (CCP)e karşı otoantikorlar RA için yüksek özgüllükleri nedeniyle özellikle dikkati çekmektedirler. Çalışmanın amacı eklem tutulumu olan veya olmayan BH ile anti-CCP ilişkisini belirlemek ve sonuçları romatoid artrit (RA) ve osteoartrit (OA) ile karşılaştırmaktır. Materyal ve Metot: Anti-CCP antikorları BH olan 30 hastada, RA olan 16 hastada ve OA olan 14 hastada ölçüldü. 30 BH hastasının onaltısında artrit vardı, geri kalanlarda hiçbir eklem tutulumu yoktu. Bulgular: BD tanısı ve aynı zamanda artriti olan sadece bir hastada (%3.3), anti-CCP pozitifliği vardı. RA olan hastaların onbiri (69%) ve OA olanların birinde (%7) anti-CCP antikor düzeyi katof değerin üstünde idi. Anti- CCP antikor düzeyi ile BH (P>0,05) ve OA (P>0,05) arasında istatistiksel olarak anlamlı ilişki yoktu ancak RA, BH ve osteoartritten anlamlı şekilde ayırt edilebilir (p< 0.01). Sonuç: Anti-CCP antikorlarının BH ve eklem tutulumunda tanısal değeri yoktur ve sonuçlar noninflamatuar bir eklem hastalığı olan OAden farklı değildir. Ileri çalışmalara ihtiyaç vardır, ancak biz bu otoantikorların RA ve BH artriti ayırıcı tanısında kullanılabileceğini düşünmekteyiz.

Anahtar Kelimeler:

Peptidler, siklik, Antikorlar, Behçet sendromu, Artrit, romatoid, Osteoartrit

Eklem tutulumu olan veya olmayan Behçet hastalarında anti-CCP antikorları

Objective: Articular involvement is an important component of Behcets disease, which occasionally can be the only initial manifestation that makes the differential diagnosis difficult. Autoantibodies to cyclic citrullinated peptide are particularly remarkable because of their high specificity for RA. The objective of the study was to determine the association of anti-CCP in BD with or without articular involvement, and to compare the results with rheumatoid arthritis and osteoarthritis (OA). Methods: Anti-CCP antibodies were measured in 30 patients with BD, 16 patients with RA, and 14 with OA. Sixteen of 30 BD patients had experienced arthritis, the remainder had no articular involvement. Results: Only one (3.3%) patient diagnosed with BD, who also suffered from arthritis, had anti-CCP positivity. Eleven (69%) patients with RA and one (7%) with OA had anti-CCP antibodies above the cut-off level. There was no statistically significant correlation between anti- CCP antibodies and BD (P>0.05), and OA (P>0.05), however, RA can be distinguished significantly from BD and osteoarthritis (P<0.01). Conclusions: Anti-CCP antibodies have no diagnostic value in BD and its articular involvement, and the results are not different from OA which is a noninflammatory articular disease. Further studies are needed, but we believe that these autoantibodies can be used in differential diagnosis of RA and BD arthritis.

Keywords:

Peptides, Cyclic, Antibodies, Behcet Syndrome, Arthritis, Rheumatoid, Osteoarthritis,

PDF

___

1. Yazici H, Yurdakul S, Hamuryudan V, Fresko I. Behçets Syndrome. Edited By: Hochberg MC, Silman AJ, Smolen JS, Weinblatt ME, Weisman MH. Rheumatology (Third Edition), Edinburgh, Mosby 2003; 1665-69.
2. Tursen U, Gurler A, Boyvat A. Evaluation of clinical findings according to sex in 2313 Turkish patients with Behçet's disease. Int J Dermatol 2003;42(5):346-51.
3. Criteria for diagnosis of Behcet's disease. International Study Group for Behcet's Disease. Lancet 1990;335(18697):1078-80.
4. Yurdakul S, Yazici H, Tuzun Y, Pazarli H, Yalcin B, Altac M, et al. The arthritis of Behcets disease: a prospective study. Ann Rheum Dis 1983;42(5):505-15.
5. Kim HA, Choi KW, Song YW. Arthropathy in Behcets disease. Scand J Rheumatol 1997;26(2):125-9.
6. Gur A, Sarac AJ, Burkan YK, Nas K, Cevik R. Arthropathy, quality of life, depression, and anxiety in Behcets disease: relationship between arthritis and these factors. Clin Rheumatol 2006;25(4):524-31.
7. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31(3):315-24.
8. van Boekel MA, Vossenaar ER, van den Hoogen FH, van Venrooij WJ. Autoantibody systems in rheumatoid arthritis: specificity, sensitivity and diagnostic value. Arthritis Res 2002;4(2):87-93.
9. Nishimura K, Sugiyama D, Kogata Y, Tsuji G, Nakazawa T, Kawano S, et al. Meta-analysis: diagnostic accuracy of anti-cyclic citrullinated peptide antibody and rheumatoid factor for rheumatoid arthritis. Ann Intern Med 2007;146(11):797-808.
10. Fathi NA, Ezz-Eldin AM, Mosad E, Bakry RM, Hamed HB, Ahmed S, et al. Diagnostic performance and predictive value of rheumatoid factor, anti-cyclic-citrullinated peptide antibodies and HLA-DRB1 locus genes in rheumatoid arthritis. Int Arch Med 2008;1(1):20.
11. Dubrous P, Gardet V, Hugard I. Value of anti-cyclic citrullinated peptides antibodies in comparison with rheumatoid factor for rheumatoid arthritis diagnosis. Pathol Biol (Paris) 2005;53(2):63-7.
12. Bas S, Perneger TV, Seitz M, Tiercy JM, Roux-Lombard P, Guerne PA. Diagnostic tests for rheumatoid arthritis: comparison of anti-cyclic citrullinated peptide antibodies, anti-keratin antibodies, and IgM rheumatoid factors. Rheumatology (Oxford) 2002;41(7):809-14.
13. Jansen AL, van der Horst-Bruinsma I, van Schaardenburg D, van de Stadt RJ, de Koning MH, Dijkmans BA. Rheumatoid factor and antibodies to cyclic citrullinated peptide differentiate rheumatoid arthritis from undifferentiated polyarthritis in patients with early arthritis. J Rheumatol 2002;29(10):2074-6.
14. van Jaarsveld CH, ter Borg EJ, Jacobs JW, Schellekens GA, Gmelig- Meyling FH, van Booma-Frankfort C, et al. The prognostic value of the antiperinuclear factor, anti-citrullinated peptide antibodies and rheumatoid factor in early rheumatoid arthritis. Clin Exp Rheumatol 1999;17(6):689-97.
15. Vencovský J, Machácek S, Sedová L, Kafková J, Gatterová J, Pesáková V, et al. Autoantibodies can be prognostic markers of an erosive disease in early rheumatoid arthritis. Ann Rheum Dis 2003;62(5):427-30.
16. Bas S, Genevay S, Meyer O, Gabay C. Anti-cyclic citrullinated peptide antibodies, IgM and IgA rheumatoid factors in the diagnosis and prognosis of rheumatoid arthritis. Rheumatology (Oxford) 2003;42(5):677-80.
17. Schellekens GA, Visser H, de Jong BA, van den Hoogen FH, Hazes JM, Breedveld FC, et al. The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide. Arthritis Rheum 2000;43(1):155-63.
18. Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO 3rd, et al. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/ European League Against Rheumatism collaborative initiative. Arthritis Rheum 2010;62(9):2569-81.
19. Bizzaro N, Mazzanti G, Tonutti E, Villalta D, Tozzoli R. Diagnostic accuracy of the anti-citrulline antibody assay for rheumatoid arthritis. Clin Chem 2001;47(6):1089-93.
20. Pinheiro GC, Scheinberg MA, Aparecida da Silva M, Maciel S. Anticyclic citrullinated peptide antibodies in advanced rheumatoid arthritis. Ann Intern Med 2003;139(3):234-5.
21. Vasishta A. Diagnosing early-onset rheumatoid arthritis: the role of anti-CCP antibodies. Am Clin Lab 2002;21(7):34-6.
22. Saraux A, Berthelot JM, Devauchelle V, Bendaoud B, Chalès G, Le Henaff C, et al. Value of antibodies to citrulline-containing peptides for diagnosing early rheumatoid arthritis. J Rheumatol 2003;30(12):2535-9.
23. Jansen LM, van Schaardenburg D, van der Horst-Bruinsma I, van der Stadt RJ, de Koning MH, Dijkmans BA. The predictive value of anticyclic citrullinated peptide antibodies in early arthritis. J Rheumatol 2003;30(8):1691-5.
24. Meyer O, Labarre C, Dougados M, Goupille P, Cantagrel A, Dubois A, et al. Anticitrullinated protein/peptide antibody assays in early rheumatoid arthritis for predicting five year radiographic damage. Ann Rheum Dis 2003;62(2):120-6.
25. Dubucquoi S, Solau-Gervais E, Lefranc D, Marguerie L, Sibilia J, Goetz J, et al. Evaluation of anti-citrullinated filaggrin antibodies as hallmarks for the diagnosis of rheumatic diseases. Ann Rheum Dis 2004;63(4):415-9.
26. Matsui T, Shimada K, Tohma S. Anti-cyclic citrullinated peptide antibody in rheumatic diseases other than rheumatoid arthritis. Clin Rheumatol 2006;25(2):610-1.
27. Fabien N, Olsson NO, Goetz J, Johanet C, Escande A, Bardin N, et al. Prevalence of Autoantibodies to Cyclic Citrullinated Peptide in Patients with Rheumatic Diseases other than Rheumatoid Arthritis: A French Multicenter Study. Clin Rev Allergy Immunol 2008;34(1):40-4.
28. Gottenberg JE, Mignot S, Nicaise-Rolland P, Cohen-Solal J, Aucouturier F, Goetz J, et al. Prevalence of anti-cyclic citrullinated peptide and anti-keratin antibodies in patients with primary Sjögren's syndrome. Ann Rheum Dis 2005;64(1):114-7.
29. Korendowych E, Owen P, Ravindran J, Carmichael C, McHugh N. The clinical and genetic associations of anti-cyclic citrullinated peptide antibodies in psoriatic arthritis. Rheumatology (Oxford) 2005;44(8):1056- 60.
30. Chan MT, Owen P, Dunphy J, Cox B, Carmichael C, Korendowych E, et al. Associations of erosive arthritis with anti-cyclic citrullinated peptide antibodies and MHC Class II alleles in systemic lupus erythematosus. J Rheumatol 2008;35(1):77-83.
31. Tobon GJ, Correa PA, Anaya JM. Anti-cyclic citrullinated peptide antibodies in patients with primary Sjogrens syndrome. Ann Rheum Dis 2005;64(5):791-2.
32. Vander Cruyssen B, Hoffman IE, Zmierczak H, Van den Berghe M, Kruithof E, De Rycke L. Anti-citrullinated peptide antibodies may occur in patients with psoriatic arthritis. Ann Rheum Dis 2005;64(8):1145-9.
33. Lee DM, Schur PH. Clinical utility of the anti-CCP assay in patients with rheumatic diseases. Ann Rheum Dis 2003;62(8):870-4.
34. Altman R, Alarcón G, Appelrouth D, Bloch D, Borenstein D, Brandt K, et al. The American College of Rheumatology criteria for the classification and reporting of osteoarthritis of the hip. Arthritis Rheum 1991;34(5):505- 14.
35. Altman R, Asch E, Bloch D, Bole G, Borenstein D, Brandt K, et al. Development of criteria for the classification and reporting of osteoarthritis. Classification of osteoarthritis of the knee. Diagnostic and Therapeutic Criteria Committee of the American Rheumatism Association. Arthritis Rheum 1986;29(8):1039-49.
36. Damián-Abrego GN, Cabiedes J, Cabral AR. Anti-citrullinated peptide antibodies in lupus patients with or without deforming arthropathy. Lupus 2008;17(4):300-4.
37. Koca SS, Akbulut H, Dag S, Artas H, Isik A. Anti-cyclic citrullinated peptide antibodies in rheumatoid arthritis and Behçet's disease. Tohoku J Exp Med 2007;213(4):297-304.